68 Days
Source:
مباشر
_1777294237270_124456903.png&w=64&q=75){kind=small}
Silkway stock drops 19% after postponement of new cancer treatment launch
The stock of SilkWay Company dropped by approximately 19% after the postponement of the launch of its new FDA-approved breast cancer drug, which was scheduled to be released in the third quarter of the year. Obtaining approval for the drug, called "Reftabrik," is an important step, as it reduces the risk of disease progression by 76%. However, it faces challenges related to side effects such as oral inflammation, which affects 72% of patients. The launch price has not been revealed yet, but it is expected to be higher than current treatments, with sales projections reaching up to $36 million in 2026.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)